Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 3:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,365 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bacterial Infection Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Enteroaggregative E.Coli (EAEC)

NCT00362869
View directory record Official record
Conditions
Escherichia Coli Infections
Interventions
Levofloxacin, Placebo, Enteroaggregative E. coli (EAEC)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2016 · Synced Oct 25, 2026, 3:35 AM EDT
Active, not recruiting No phase listed Observational

Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia

NCT05296590
View directory record Official record
Conditions
Bacteremia, Bacteremia Sepsis, Sepsis, Septic Shock, Severe Sepsis, Emergency Departments, Continuity of Patient Care
Interventions
Monocyte Distribution Width (MDW) , observation
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Not applicable Interventional

A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.

NCT00002113
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 3:35 AM EDT
Completed No phase listed Observational

BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia

NCT02220790
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
120 Days to 18 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers

NCT00384397
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
249 Days to 305 Days
Enrollment
1,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
39
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Angiotech Central Venous Catheter to Prevent Bacterial Catheter Colonization

NCT00288418
View directory record Official record
Conditions
Bacterial Infections
Interventions
Central Venous Catheter
Device
Lead sponsor
Angiotech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 25, 2026, 3:35 AM EDT
Recruiting Not applicable Interventional

Clinical Protocol CERN Feasibility Study

NCT06933420
View directory record Official record
Conditions
Bacterial Vaginosis, Fungal Vaginal Infections
Interventions
Cern Device
Device
Lead sponsor
Cern Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Irvine, California • Orange, California • Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

NCT03615482
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, QIV, Matching Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Not applicable Interventional Results available

Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias

NCT03244917
View directory record Official record
Conditions
Dementia, Infection, Bacterial
Interventions
TRAIN-AD
Behavioral
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
21 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 25, 2026, 3:35 AM EDT
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 25, 2026, 3:35 AM EDT
Recruiting Phase 2Phase 3 Interventional

Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

NCT03474029
View directory record Official record
Conditions
Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeks, Rifapentine and Isoniazid weekly for 12 weeks, Rifampin and Isoniazid daily for 12 weeks, Rifampin daily for 16 weeks
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
3,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
7
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Manhattan, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 3:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant

NCT05695196
View directory record Official record
Conditions
Staphylococcus Aureus, Microbial Colonization, Neonatal Infection
Interventions
nasal microbiota transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
Up to 60 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP

NCT01531530
View directory record Official record
Conditions
Shigella
Interventions
CVD 1208S, a Shigella flexneri 2a live, oral vaccine, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 2 Interventional Results available

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

NCT01209078
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
GSK1322322, Linezolid, GSK1322322 placebo, Linezolid placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Anniston, Alabama • Chula Vista, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis

NCT02563327
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, Moxifloxacin, Rifampin, Isoniazid, Pyrazinamide, Ethambutol, Pyridoxine
Drug · Dietary Supplement
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 25, 2026, 3:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome

NCT06283355
View directory record Official record
Conditions
Staphylococcus Aureus, Microbial Colonization, Neonatal Infection
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 3:35 AM EDT
Terminated Phase 3 Interventional

Caspofungin Study for Fungal Infections in Adults in Critical Care Settings

NCT00095316
View directory record Official record
Conditions
Candidiasis
Interventions
Caspofungin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 2 Interventional

A Randomized, Double-Blind Study of 566C80 Versus Septra (Sulfamethoxazole/Trimethoprim) for the Treatment of Pneumocystis Carinii Pneumonia in AIDS Patients

NCT00000655
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Atovaquone, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Birmingham, Alabama • Harbor City, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 25, 2026, 3:35 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 3:35 AM EDT
Terminated Phase 3 Interventional

A Study to Assess the Safety, Tolerability, Effectiveness and Absorption of Exodif™ Tablets in Clostridium Difficile-associated Diarrhea

NCT00466635
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous, Diarrhea, Clostridium Difficile
Interventions
GT267-004 (tolevamer potassium sodium)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Modesto, California • Honolulu, Hawaii • Maywood, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Oct 25, 2026, 3:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

NCT01689155
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 23 Months
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 25, 2026, 3:35 AM EDT
Completed Not applicable Interventional

Pulsed Dye Laser Treatment of Onychomycosis

NCT01915355
View directory record Official record
Conditions
Onychomycosis
Interventions
Pulsed Dye Laser for the treatment of nail fungus
Device
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 25, 2026, 3:35 AM EDT